1 Review Article

2 A Review of Dosages of Chloroquine and Hydroxychloroquine for COVID-19 in registered 3 Clinical Trials during First Quarter of 2020

4 Divya RSJB Rana, MS¹, Santosh Dulal, MS, PhD^{1, 2*}

5 ¹Hari Khetan Multiple Campus, Birgunj, Nepal (affiliated to Tribhuvan University, Kirtipur, Nepal)

6 ²Department of Biotechnology, National College, Tribhuvan University, Kathmandu, Nepal

7

8 Running Title: Dosages of chloroquine in clinical trials

9 *Corresponding author:

10 Dr. Santosh Dulal

11 Department of Biotechnology, National College, Tribhuvan University, Kathmandu, Nepal

12 email: drsantoshdulal@gmail.com

13

14

15 Keywords: COVID-19, Chloroquine, Hydroxychloroquine, Dosages

16

17

18

19

Abstract: □

Background: The novel corona virus disease 2019 (COVID-19) pandemic has been causing a massive global public health havoc. Use of quinolones for treatment of COVID-19 was a matter of huge discussion in scientific community. Falsified data about efficacy of the drug against COVID-19 disseminated. This review was designed to study the dosages of chloroquine and hydroxychloroquine planned to be administered in clinical trials registered up to March 2020.

Summary: Inclusion of chloroquine and hydroxychloroquine for COVID-19 treatment in Chinese national treatment guideline in the early days of the pandemic prompted numerous clinical trials in many countries to authenticate the efficacy of the drugs. Trials were designed to include chloroquine or hydroxychloroquine singly or in combination with other drugs. Almost all of the trials planned oral administration except few which used aerosol inhalation. In the later half of 2020, systematic reviews and results of those clinical trials point out the inefficacies and inadvertent adverse events due to the use of these quinolone drugs for COVID-19.

Conclusion: This study reviews the various dosages of chloroquine and hydroxychloroquine utilized in published and under-study clinical trials as assessed during the end of March 2020. Specifically, clinical trials registered in Chinese and US trial registries were examined.

Background

Coronavirus disease 2019 (COVID-19) is an infectious disease of respiratory tract of potential zoonotic origin¹. Severe acute respiratory syndrome (SARS) corona virus – 2, (SARS-CoV-2), the etiological agent of COVID-19, causes a serious or life-threatening disease or condition, including severe respiratory illness¹. The public health concerns caused by the outbreak of COVID-19 was declared as a “public health emergency of international concern” on 31 January and “pandemic on 11 March 2020 by World Health Organization². Impacts of the COVID-19 pandemic touched all the corners of the globe leading to colossal economic and public health crisis. The reported mortality rate for COVID-19 in the early days was around 3%³ and the mortality rates vary depending on geographical regions, age distributions and co-morbidities⁴ making it a subject of debate⁵.

In the early days of the pandemic, the Chinese Government included chloroquine phosphate in the list of antiviral therapies for the treatment of novel coronavirus pneumonia or COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in its 6th and 7th versions of the official guidelines for the Prevention, Diagnosis, and Treatment of Pneumonia caused by COVID-19^{6,7}. Conclusive research on the potential therapeutic applications for the disease could have saved lives and prevent the rapid viral transmission. Chloroquine phosphate is an old drug used for the treatment of malaria caused by *Plasmodium species*⁸. Chloroquine phosphate can also be replaced with another member of its family, hydroxychloroquine⁹. The active compound chloroquine constitutes 60% in chloroquine phosphate and 77.5% in hydroxychloroquine respectively.

Earlier in vitro studies had shown efficacy of chloroquines against coronaviruses. Mechanism of actions of chloroquine or hydroxychloroquine had been studied for both SARS-CoV and SARS-CoV-2. A study using Vero E6 cells found that treatment of the cells with chloroquine either before or after infection with SARS-CoV could prevent infection or treat the infected cells suggesting both prophylactic and therapeutic effect¹⁰. The study found chloroquine disturbed the biochemical maturation of the cellular receptor, angiotensin converting enzyme 2 (ACE2), for SARS-CoV, and increased the pH of intracellular virus-laden vesicles inhibiting the viral normal multiplication processes. The receptor for SARS-CoV-2 is also highly predicted of being ACE2¹¹. In vitro studies for SARS-CoV-2 also found chloroquine and hydroxychloroquine, a less-toxic derivative of chloroquine to be able to effectively inhibit viral growth¹¹. They found the viral biological processes in the endosomes were affected by the anti-malarial agents. While the reported 50% effective concentration of the drugs were higher than the normal serum concentration of drugs in people taking these drugs, the concentrations in lungs and other vital organs are higher¹² and could lend support for the idea that the drug could perhaps be useful. The most common side-effect of these are retinopathy and other side-effects precipitating due to higher concentrations of the compounds in blood.

The recommended 3-day chloroquine phosphate dosage for malaria treatments for adults is 1 gm orally followed by 500 mg after 6-8 hours in the first day and 500 mg per day for second and the third day⁸. Similarly, the 3-day dosage for hydroxychloroquine is 800 mg orally followed by 400 mg after 6-8 hours in the first day and 400 mg per day for second and third day⁹.

This study was specifically conducted to examine the various dosages of chloroquine and hydroxychloroquine utilized in clinical trials registered in China and USA for the treatment of pneumonia caused by SARS-CoV-2. The guidelines by the Chinese government has postulated the dose of 500 mg twice a day for 7 days for adults aged 18-65 years and weighing more than 50 kg; and initial dose of 500 mg twice a day for first two days and 500 mg per day for days 3 through 7 for adults of weight less than 50 kg⁷.

Methods:

A systematic search of registered clinical trials was carried (Figure 1, PRISMA flow-chart). The list of clinical trials registered in China in a ready-made excel spreadsheet format was downloaded from the Chinese clinical trial registry¹³ on 30th March, 2020 provided in the website. The list of clinical trials registered in the US government clinical trial registry¹⁴ were retrieved by searching “coronavirus”

as keyword on 30th March, 2020. All the trials were filtered out based on the presence of word “chloroquine” in the title irrespective of the chemical forms of the molecule (hydroxychloroquine) or trials being carried alone or in combination with other antiviral therapies. An excel spreadsheet file was prepared based on various headings including intervention groups, randomization status, sample sizes, etc. Univariate statistics was used to report the methodologies of the trials.

Results:

As of 30th March 2020, 547 trials were registered in the Chinese clinical trial registry starting from 23rd January, 2020. 25 (4.6%, 25/547) clinical trials used the word chloroquine in their titles. Five of them were reported to had been canceled, one was a prophylactic study and one another trial information could not be retrieved. Eighteen (3.3%, 18/547) clinical trials from the Chinese registry were used for the downstream analysis. As of 30th March 2020, 184 entries were obtained by searching for coronavirus related clinical trials in the US clinical trial registry of which only 153 were registered after 1st January 2020. Out of 153 registrations, 20 (13.1%, 20/153) were found to use chloroquine. Four of these were registered from China, 3 from Brazil, 2 each from France, Mexico, US and Canada, and 1 each from Thailand, South Korea, United Kingdom, Norway and Turkey. Two of the studies from US, and 1 each from the United Kingdom, Mexico and Turkey were prophylactic study for healthy people at risk of infection. Thus 15 studies from US trial registry were used for analysis. Total 33 (18+15) clinical trials utilizing the quinolones had been registered since 3rd February 2020. Six prophylactic studies are analyzed separately.

Most of the trials proposed oral chloroquine (68.2%, 15/33) or hydroxychloroquine (68.2%, 15/33) singly as treatment options, followed by chloroquine in combination with other antivirals ((13.6%, 3/33), hydroxychloroquine with azithromycin (9.1%, 2/33), chloroquine as aerosols (9.1%, 2/33), chloroquine with azithromycin (4.5%, 1/33) and hydroxychloroquine with other antivirals (4.5%, 1/33) (Table 1). The maximum quantity of chloroquine planned was 12 g in a period of 10 days (NCT04323527) and the lowest reported was 2.1 g aerosolized chloroquine (ChiCTR2000029975) in a duration on 7 days. Similarly, the maximum quantity of hydroxychloroquine proposed was 12.4 gm in a duration of 14 days (ChiCTR2000029868) and the lowest amount was 2 gm in a period of 5 days (NCT04261517). Only one of the two trials proposing aerosolized chloroquine phosphate stated the dosage. It was 2.1 gm in a period of 7 days (ChiCTR2000029975). A total of 12,894 study patients were planned to be enrolled in 33 trials. Twelve trials registered in the US registry didn't have details about sample size allocation into individual intervention arms. For the 5,842 individuals in 21 trials with information on sample sizes in individual intervention arms, 1199 patients were to get chloroquine alone, 1050 were to get hydroxychloroquine alone, 159 were to get chloroquine with other drugs, 25 were to get aerosolized chloroquines, 1320 were to get conventional treatments or placebo, and 2089 were to get other antivirals. All of the active or placebo interventions were planned to get conventional treatments or the standard care. Out of the 33 clinical trials, 4 reported that they were not designed to be randomized, two were single arm studies and didn't require randomization and 27 reported using some kind of randomization. Out of total, nine-tenth (91%, 30/33) of the studies had set 18 years old as lower age limit for inclusion criteria while two trials used 16 years, and one trial used 30 years. Similarly, upper age limit ranged from 65 to 100 years of age. All trials had planned to enroll both genders in the study.

Among the trials using chloroquine or hydroxychloroquine as prophylactic agent (Table 3), 45,400 healthy at-risk population were to be enrolled, among which the UK study by the University of Oxford, planned to enroll 40,00 individuals for a duration of three months with 250 mg chloroquine daily (NCT04303507). A small dose of 200 mg hydroxychloroquine given every three weeks along with daily vitamin C and zinc tablets (NCT04326725) was planned in an another prophylactic study in Turkey. The ambitious projects hoped to provide low-cost option for vaccination which could not save millions of lives in coming months.

The background information in a Chinese clinical trial (ChiCTR2000029741) ¹⁵ had revealed that chloroquine phosphate (5 days medications) was fifty percent (5/10) effective compared to 20% (3/15) for combination medication of lopinavir/ritonavir (5 days medications) in Chinese COVID-19 pneumonia patients in 2020.

The Chinese government in its 6th and 7th guidelines for the treatment of novel coronavirus pneumonia had recommended use of chloroquine phosphate at specific dosages coinciding with a very brief summary article from China ¹⁶ about successful treatment of COVID-19 patients with chloroquine in China. One of the first trials using chloroquine as treatment drug for COVID-19 outside China was a non-randomized open-label clinical trial in France that enrolled hospitalized COVID-19 patients to the hydroxychloroquine (20 patients) and control arms (16 patients) concluded a positive effect of hydroxychloroquine or hydroxychloroquine plus azithromycin based on viral negativity at day 6 ¹⁷. The study played role in prompting the US FDA to give emergency use authorization for the drug ¹⁸. The study was later hugely criticized due to inappropriate patient enrollment, study design, and unethical conduct of an editor of the journal being one of the author of the article. The scientific society related to the journal shared the concern ¹⁹. A review noted the inclusion of chloroquine/hydroxychloroquine based therapy in the national guidelines of China, Korea, Netherlands, Italy, Canada and Belgium ²⁰. RECOVERY trial by the University of Oxford in the UK which enrolled 11 thousand hospitalized COVID-19 patients concluded no benefit of hydroxychloroquine ²¹. A systematic review and meta-analysis of seven randomized control trial concluded no benefit of hydroxychloroquine for mild and moderate forms of COVID-19 disease and increase in adverse events in the treatment group ²². A Cochrane review of clinical trials found no benefits of using the quinolones on mortality and mechanical ventilation of the COVID-19 patients ²³. Moreover the review found increased proportion of adverse events in the treatment arm.

Conclusion:

Currently, there are very limited information and knowledge regarding the therapeutic aspects of COVID-19 as most of the clinical trials are still undergoing and their findings have not been publicly available yet. Touret and de Lamballerie ²⁴ reported the scarcity of data in clinical trials on therapeutic aspects of chloroquine or hydroxychloroquine. They pointed out that in spite of wonderful ex vivo activities of the quinolones against influenza, dengue, chikungunya, etc. the effect failed to replicate in in vivo studies. Gao et al. ¹⁶ in an abstract-like article revealed that chloroquine phosphate had superior efficacy for controlling the inhibition of pneumonia exacerbation, disease progression and transmission in more than 100 Chinese COVID-19 patients. Scientifically sound studies and results of time-tested clinical trials are required for conclusive identification of treatment regimens. Recent and previous *in vitro* studies have shown the effectiveness of chloroquine and hydroxychloroquine against COVID-19 or other coronaviruses (Table 4) and these data prove that in results of vitro studies may not be always replicated in clinical trials.

Continued efforts to carry ethically valid clinical trials are required for the assessment of effective and safe dosage administration. This can importantly contribute to guide the medical professionals for prescribing the accurate interventions and also contribute to pharmaceutical companies for deciding appropriate manufacturing pathways.

Contributions: SD and DR conceptualized the study. SD laid out the plan of the study. DR wrote the first draft. SD and DR edited and agreed on the final draft.

Disclosure and potential conflicts of interest : The authors have no conflicts of interest to declare.

Funding Declaration: None

References:

1. Zhou P, Yang X Lou, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature*. 2020;579(7798):270-273. doi:10.1038/s41586-020-2012-7
2. WHO. WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020. <https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020>. Accessed April 2, 2020.
3. Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. *Lancet*. 2020;395:470-473. doi:10.1016/S0140-6736(20)30154-9
4. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. 2020. doi:10.1016/S0140-6736(20)30566-3
5. WHO. Estimating mortality from COVID-19. <https://www.who.int/news-room/commentaries/detail/estimating-mortality-from-covid-19>. Published 2020. Accessed February 16, 2021.
6. ChinaGov. 《新型冠状病毒肺炎诊疗方案（试行第六版）》解读_解读_中国政府网. http://www.gov.cn/zhengce/2020-02/19/content_5480958.htm. Accessed March 17, 2020.
7. ChinaGov. 《新型冠状病毒肺炎诊疗方案（试行第七版）》解读_解读_中国政府网. http://www.gov.cn/zhengce/2020-03/04/content_5486710.htm. Accessed March 17, 2020.
8. Drugs.com. Chloroquine Dosage Guide with Precautions - Drugs.com. <https://www.drugs.com/dosage/chloroquine.html>. Accessed March 17, 2020.
9. Drugs.com. Hydroxychloroquine Dosage Guide with Precautions - Drugs.com. <https://www.drugs.com/dosage/hydroxychloroquine.html>. Accessed March 17, 2020.
10. Vincent MJ, Bergeron E, Benjannet S, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. *Virol J*. 2005;2(1):69. doi:10.1186/1743-422X-2-69
11. Liu J, Cao R, Xu M, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. *Cell Discov*. 2020;6(1):16. doi:10.1038/s41421-020-0156-0
12. Browning DJ, Browning DJ. Pharmacology of Chloroquine and Hydroxychloroquine. In: *Hydroxychloroquine and Chloroquine Retinopathy*. Springer New York; 2014:35-63. doi:10.1007/978-1-4939-0597-3_2

- 228 13. ChiCTR.org.cn. Chinese Clinical Trial Register (ChiCTR) - The world health organization
229 international clinical trials registered organization registered platform.
230 <http://www.chictr.org.cn/enindex.aspx>. Accessed March 17, 2020.
- 231 14. Clinicaltrials.org. Home - ClinicalTrials.gov. <https://clinicaltrials.gov/>. Accessed March 17,
232 2020.
- 233 15. Xia J. 中国临床试验注册中心 - 世界卫生组织国际临床试验注册平台一级注册机构.
234 <http://www.chictr.org.cn/showproj.aspx?proj=49263>. Accessed March 17, 2020.
- 235 16. Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in
236 treatment of COVID-19 associated pneumonia in clinical studies. doi:10.5582/bst.2020.01047
- 237 17. Gautret P, Lagier J-C, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of
238 COVID-19: results of an open-label non-randomized clinical trial. *Int J Antimicrob Agents*.
239 March 2020;105949. doi:10.1016/j.ijantimicag.2020.105949
- 240 18. Bright R. *Letter of Authorization - Chloroquine Phosphate and Hydroxychloroquine Sulfate.*;
241 2020. [https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f398f8a9-92f3-47cb-81c2-](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f398f8a9-92f3-47cb-81c2-6078806a464d)
242 [6078806a464d](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f398f8a9-92f3-47cb-81c2-6078806a464d). Accessed February 16, 2021.
- 243 19. ISAC. Statement on IJAA paper | International Society of Antimicrobial Chemotherapy.
244 <https://www.isac.world/news-and-publications/official-isac-statement>. Published 2020. Accessed
245 February 16, 2021.
- 246 20. Singh AK, Singh A, Shaikh A, Singh R, Misra A. Chloroquine and hydroxychloroquine in the
247 treatment of COVID-19 with or without diabetes: A systematic search and a narrative review
248 with a special reference to India and other developing countries. *Diabetes Metab Syndr Clin Res*
249 *Rev.* 2020;14(3):241-246. doi:10.1016/j.dsx.2020.03.011
- 250 21. RECOVERY TRIAL. No clinical benefit from use of hydroxychloroquine in hospitalised
251 patients with COVID-19 — RECOVERY Trial. [https://www.recoverytrial.net/news/statement-](https://www.recoverytrial.net/news/statement-from-the-chief-investigators-of-the-randomised-evaluation-of-covid-19-therapy-recovery-trial-on-hydroxychloroquine-5-june-2020-no-clinical-benefit-from-use-of-hydroxychloroquine-in-hospitalised-patients-with-covid-19)
252 [from-the-chief-investigators-of-the-randomised-evaluation-of-covid-19-therapy-recovery-trial-](https://www.recoverytrial.net/news/statement-from-the-chief-investigators-of-the-randomised-evaluation-of-covid-19-therapy-recovery-trial-on-hydroxychloroquine-5-june-2020-no-clinical-benefit-from-use-of-hydroxychloroquine-in-hospitalised-patients-with-covid-19)
253 [on-hydroxychloroquine-5-june-2020-no-clinical-benefit-from-use-of-hydroxychloroquine-in-](https://www.recoverytrial.net/news/statement-from-the-chief-investigators-of-the-randomised-evaluation-of-covid-19-therapy-recovery-trial-on-hydroxychloroquine-5-june-2020-no-clinical-benefit-from-use-of-hydroxychloroquine-in-hospitalised-patients-with-covid-19)
254 [hospitalised-patients-with-covid-19](https://www.recoverytrial.net/news/statement-from-the-chief-investigators-of-the-randomised-evaluation-of-covid-19-therapy-recovery-trial-on-hydroxychloroquine-5-june-2020-no-clinical-benefit-from-use-of-hydroxychloroquine-in-hospitalised-patients-with-covid-19). Published 2020. Accessed February 17, 2021.
- 255 22. Pathak DSK, Salunke DAA, Thivari DP, et al. No benefit of hydroxychloroquine in COVID-19:
256 Results of Systematic Review and Meta-Analysis of Randomized Controlled Trials”. *Diabetes*
257 *Metab Syndr Clin Res Rev.* 2020;14(6):1673-1680. doi:10.1016/j.dsx.2020.08.033
- 258 23. Singh B, Ryan H, Kredo T, Chaplin M, Fletcher T. Chloroquine or hydroxychloroquine for
259 prevention and treatment of COVID-19. *Cochrane Database Syst Rev.* 2021;(2).
260 doi:10.1002/14651858.CD013587.pub2
- 261 24. Touret F, de Lamballerie X. Of chloroquine and COVID-19. *Antiviral Res.* 2020;177:104762.
262 doi:10.1016/j.antiviral.2020.104762
263

Table 1: Use of different forms of chloroquine in clinical trials

Type of trials	Trials (%)*
Chloroquine phosphate	15 (68.2%)
Chloroquine phosphate with other antivirals	3 (13.6%)
Chloroquine with azithromycin	1 (4.5%)
Hydroxychloroquine	15 (68.2%)
Hydroxychloroquine with others	1 (4.5%)
Hydroxychloroquine with azithromycin	2 (9.1%)
Chloroquine phosphate as aerosol inhalation	2 (9.1%)
Total	33 (100%)

*Few trials have one or more types together in same study

Table 2: Dosages and characteristics of the registered clinical trials

Trial No.	Arms in Trial	Treatment Dosage* (Only CQ and HCQ arms discussed)	Placebo/ Standard care arm presence	Randomiza tion	Country
ChiCTR200002 9542	2	CQ: 500 mg, BD, 7 days Placebo/Standard care	Yes	No	China
ChiCTR200002 9559	3	HCQ: 100 mg, BD HCQ: 200 mg BD Placebo/Standard Care	Yes	Yes	China
ChiCTR200002 9609	3	CQ: 250 mg CQ+antiviral: 250 mg Antiviral	No	No	China
ChiCTR200002 9741	2	CQ: NA Antiviral	No	No	China
ChiCTR200002 9826	2	CQ: 2 tabs, BD Placebo/Standard Care	Yes	Yes	China
ChiCTR200002 9837	2	CQ: 2 tabs, BD Placebo/Standard Care	Yes	Yes	China
ChiCTR200002 9868	2	HCQ: D1-3: 400 mg, TDS; D4-14: 400 mg BD Placebo/Standard Care	Yes	Yes	China
ChiCTR200002 9898	2	CQ: D1-3: 500 mg, BD; D4-5: 250 mg, BD	No	Yes	China

		HCQ: D1: 600 mg BD, D2-5: 200 mg, BD			
ChiCTR2000029935	1	CQ: NA	No	Single Arm	China
ChiCTR2000029939	2	CQ: NA Placebo/Standard care	Yes	Yes	China
ChiCTR2000029975	1	CQ: 150 mg aerosolized, q12h, 7 days	No	Single Arm	China
ChiCTR2000029988	2	CQ: NA Placebo/Standard Care	Yes	Yes	China
ChiCTR2000029992	3	CQ: D1-2: 500 mg BD; D3-14: 250 mg, BD HCQ: 200 mg, BD, 14 days Placebo/Standard care	Yes	Yes	China
ChiCTR2000030054	3	CQ: D1-2: 500 mg BD; D3-14: 250 mg, BD HCQ: 200 mg, BD, 14 days Placebo/Standard care	Yes	Yes	China
ChiCTR2000030417	2	CQ: aerosols Placebo/Standard care	Yes	Yes	China
ChiCTR2000030718	2	CQ: NA Placebo/Standard Care	Yes	Yes	China
NCT04303299	8	HCQ: Arm 1: 800 mg/day, 10 days with different antivirals; Arm2, 6, 7: 400 mg/day, 10 days with different antivirals Placebo/Standard care	Yes	Yes	Thailand
NCT04261517	2	HCQ: 400 mg/day, 5 days Placebo/Standard care	Yes	Yes	China
NCT04286503	4	CQ: NA	No	Yes	China
NCT04307693	3	HCQ: 200 mg, BD, 7-10 days Placebo/Standard care	Yes	Yes	South Korea
ChiCTR2000030987	3	CQ: NA, with antivirals Placebo/Standard care	Yes	Yes	China
ChiCTR2000031204	2	CQ: NA Placebo/Standard care	Yes	Yes	China
NCT04316377	2	HCQ: 400 mg, BD, 7 days Placebo/Standard care	Yes	Yes	Norway
NCT04315948	5	HCQ: D1: 400 mg, BD; D2-10: 200 mg OD Placebo/Standard care	Yes	Yes	France
NCT04315896	2	HCQ: 200 mg, BD, 10 days Placebo/Standard care	Yes	Yes	Mexico
NCT04319900	3	CQ: D1: 500 mg, BD; D2-3: 500 mg, OD; D4-10: 250 mg, OD; all with other antivirals Placebo/Standard care	Yes	Yes	China

NCT04321278	2	HCQ: Arm 1: 400 mg, BD, 10 days, with azithromycin; Arm 2: 400 mg, BD, 10 days;	No	Yes	Brazil
NCT04321616	3	HCQ: D1: 600 mg, BD; D2-10: 300 mg, TDS Placebo/Standard care	Yes	Yes	Norway
NCT04321993	4	HCQ: 400 mg, BD, 10 days	No	No	Canada
NCT04322123	3	HCQ: Arm 1: 400 mg, BD, 7 days; Arm 2: 400 mg, BD, 7 days with azithromycin Placebo/Standard care	Yes	Yes	Brazil
NCT04323527	2	CQ: Arm 1 (low dose): D1: 450 mg, BD; D2-5: 450 mg, OD; Arm 2 (high dose): 600 mg, BD, 10 days	No	Yes	Brazil
NCT04324463	2	CQ: Body wt. >50 kg: 500 mg, BD, 7 days; Body wt. <50 kg: D1-2: 500 mg, BD; D3-7: 500 mg, OD; both groups with azithromycin Placebo/Standard care	Yes	Yes	Canada
NCT04325893	2	HCQ: D1: 400 mg, BD; D2-8: 200 mg, BD Placebo/Standard care	Yes	Yes	France

*CQ, chloroquine; HCQ, hydroxychloroquine; Not all studies provided all the details of dosages

Table 3: Dosages and characteristics of prophylactic clinical trials

Trial No.	Arms in Trial	Treatment Dosage* (Only CQ and HCQ arms discussed)	Placebo/Standard care arm presence	Randomization	Country
ChiCTR2000029803	4	HCQ: High dose; Low dose	No	Yes	China
NCT04303507	2	CQ: D1: 10 mg/day; 250 mg, OD, 3 months Placebo	Yes	Yes	UK
NCT04308668	2	HCQ: D1: 800 mg followed by 600 mg after 6-8 hrs; 600 mg, OD, 4 days Placebo	Yes	Yes	US
NCT04318015	4	HCQ: High-risk group: 200 mg, OD, 60 days; Low-risk group: 200 mg, OD, 60 days	Yes	Yes	Mexico

		Placebo: High-risk and Low-risk group both placebo			
NCT04318444	2	HCQ: D1: 400 mg, BD; D2-5: 200 mg, BD Placebo	Yes	Yes	US
NCT04326725	1	HCQ: 200 mg, once in three weeks, with daily vitamin C and zinc tabs	Yes	No	Turkey

*CQ, chloroquine; HCQ, hydroxychloroquine; Not all studies provided all the details of dosages

Table 4: In vitro studies using chloroquine/hydroxychloroquine against coronavirus.

Virus	Host	Drug	EC50* (mcM)	Author, Year
SARS-CoV-2	Vero	Hydroxychloroquine sulf.	0.72 (poi)	Yao 2020
SARS-CoV-2	Vero	Chloroquine phosp.	5.47 (poi)	Yao 2020
SARS	Vero E6	Chloroquine	4.1 (poi)	de Wilde 2014
MERS	Huh7	Chloroquine	3.0 (poi)	de Wilde 2014
HCoV-229E	Huh7	Chloroquine	3.3 (poi)	de Wilde 2014
SARS	Vero E6	Chloroquine	1 mcM (pri)	Vincent 2005
SARS	Vero E6	Chloroquine	4.4 mcM (poi)	Vincent 2005
rHCoV-OC43	BHK-21	Chloroquine	IC50 0.33 (poi)	Shen 2016
HCoV-OC43	HRT-18	Chloroquine phosp.	0.306 mcM (poi)	Keyaerts 2009
MERS	Dendritic cell	Chloroquine diphosp.	Not effective	Cong 2018
SARS	Vero E6	Chloroquine	IC50 8.8 (poi)	Keyaerts 2004
FIPV	CRFK	Chloroquine diphosp.	IC50 16.63 (pri)	McDonagh 2014
FIPV	CRFK	Chloroquine diphosp.	IC50 0.38 (24h pri)	McDonagh 2014
FIPV	CRFK	Chloroquine diphosp.	IC50 28.87 (48h pri)	McDonagh 2014
MERS	Vero E6	Chloroquine diphosp.	6.3 (pri)	Dyall 2014

SARS	Vero E6	Chloroquine diphosp.	6.5 (pri)	Dyall 2014
MERS	Vero E6	Hydroxychloroquine sulf.	8.3 (pri)	Dyall 2014
SARS	Vero E6	Hydroxychloroquine sulf.	7.9 (pri)	Dyall 2014
SARS	Vero 76	Chloroquine	2.5 (sti)	Barnard 2006
SARS	Vero 76	Chloroquine diphosp.	6.0 (sti)	Barnard 2006
SARS-CoV-2	Vero E6	Chloroquine	1.13 (pri)	Wang 2020

50% effective concentration unless stated; IC50: 50% inhibitory concentration; poi: post infection; pri: pre infection; sti: drug and infection at same time

**References in supplementary information

289
290
291

Figure 1: PRISMA flow diagram for strategy for search of registered clinical trials